The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Melafind is currently undergoing Phase III testing. If these results are positive (and I cannot comment on the trial since I do not know any of the details) then presumably the device will be approved. If practitioners cannot be reimbursed for its use by insurance companies, it will be difficult...
CMS has ecome very aggressive about denying coverage of so called negative impact therapy What is the real motive behind the CMS debate and various therapies? Cancer care has seen this time and time again.
Is Lapatinib a major accomplishment for GSK? Was the recent phase III that led to approval understood? Are there threats to Lapatinib in the near furure?
Provenge was shot down by the FDA this month. This active specific immunotherapy for advanced prostate cancer failed to reach any of its primary or secondary endpoints. The survival "benefit" touted in the lay press is likely a statistical anomaly but a large scale study is pending (if the company ...
There is new biopharm company Exelixis that is putting a large amount of effort in developing a variety of small molecule TKI's TKI's are becoming a crowded area of anti cancer development
PET scans have become a major tool in oncologyPET scans have endless potential in applications to managing cancer patientsPET scans are "easier said than done" in regards to third party payorsPET scan are over used?
The most successful treatment for GIST has demonstrated a benefit in the adjuvant settingThe use of Gleevec in this setting while a major accomplishment for any anti-tumor therapy, will have a modest impact on sales of Gleevec
Xcytrin (motexafin gadolinium) is a rationally designed compound that concentrates selectively in cancer cells, inducing redox stress and triggering apoptosis (cell suicide). Xcytrin has been shown to be synergistic with radiation and in the pivotal phase III SMART trial was shown to improve the...